AR086673A1 - RESPUESTAS MEJORADAS MEDIADAS POR LES-DC DE CELULAS B QUE SECRETAN IgG E IgA - Google Patents

RESPUESTAS MEJORADAS MEDIADAS POR LES-DC DE CELULAS B QUE SECRETAN IgG E IgA

Info

Publication number
AR086673A1
AR086673A1 ARP120101977A ARP120101977A AR086673A1 AR 086673 A1 AR086673 A1 AR 086673A1 AR P120101977 A ARP120101977 A AR P120101977A AR P120101977 A ARP120101977 A AR P120101977A AR 086673 A1 AR086673 A1 AR 086673A1
Authority
AR
Argentina
Prior art keywords
expression
cells
level
sindecan
lupus erythematosus
Prior art date
Application number
ARP120101977A
Other languages
English (en)
Inventor
Sangkon Oh
Maria Virginia Pascual
Jacques F Banchereau
Christine Morel
Hyemee Joo
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of AR086673A1 publication Critical patent/AR086673A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Método para tratar un paciente en riesgo o con un diagnóstico de lupus eritematoso sistémico (LES) determinando la expresión total de sindecano-1 en una o más células de un pacientes que se sospecha que está afectado por LES y predecir la eficacia de un agente farmacéutico para su tratamiento. Una reducción en la expresión total de sindecano-1 en las células del paciente, en comparación con la expresión de sindecano-1 en células normales, indica una predisposición a la responsividad a una terapia con un agente anti-neoplásico, y la terapia comprende administrar una cantidad eficaz del agente farmacéutico al paciente.Reivindicación 1: Un método para diagnosticar el lupus eritematoso sistémico (SLE), que comprende los siguientes pasos: determinar el nivel de expresión de sindecan-1 en una muestra que ha sido aislada con antelación; comparar el nivel de expresión de sindecan-1 en la muestra con el nivel de expresión normal en una muestra de control, obtenida de un tejido normal conocido; y correlacionar el nivel de expresión de sindecan-1 con un diagnóstico de lupus eritematoso sistémico, donde un nivel de expresión incrementado de sindecan-1 es indicativo de un diagnóstico de lupus eritematoso sistémico.
ARP120101977A 2011-06-06 2012-06-04 RESPUESTAS MEJORADAS MEDIADAS POR LES-DC DE CELULAS B QUE SECRETAN IgG E IgA AR086673A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161493755P 2011-06-06 2011-06-06

Publications (1)

Publication Number Publication Date
AR086673A1 true AR086673A1 (es) 2014-01-15

Family

ID=47261858

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101977A AR086673A1 (es) 2011-06-06 2012-06-04 RESPUESTAS MEJORADAS MEDIADAS POR LES-DC DE CELULAS B QUE SECRETAN IgG E IgA

Country Status (3)

Country Link
US (1) US20120308578A1 (es)
AR (1) AR086673A1 (es)
WO (1) WO2012170512A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220034742A (ko) * 2019-12-24 2022-03-18 레메젠 코, 리미티드 Taci-fc 융합 단백질 및 그 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2441848A1 (de) * 2010-10-12 2012-04-18 Protagen AG Markersequenzen für systemischer Lupus Erythematodes und deren Verwendung

Also Published As

Publication number Publication date
US20120308578A1 (en) 2012-12-06
WO2012170512A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
AR084938A1 (es) Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
CR20110128A (es) Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar a un paciente de acuerdo con la respuesta predicha
BR112014013151A2 (pt) dispositivo de microagulhas incluindo um agente terapêutico peptídeo e um aminoácido, métodos para produzir e usar o dispositivo
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
AR081874A1 (es) Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3)
Chen et al. The effect of citalopram on chronic stress-induced depressive-like behavior in rats through GSK3β/β-catenin activation in the medial prefrontal cortex
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
BR112017026709A2 (pt) tratamento e diagnóstico de câncer
CL2020002047A1 (es) Métodos terapéuticos y diagnósticos para enfermedades inflamatorias mediadas por mastocitos.
ES2571111T3 (es) Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia
BR112015013374A2 (pt) dispositivo de luva hemostática e método para uso do mesmo
CO6592030A2 (es) Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa
CL2023003003A1 (es) Tratamiento y diagnóstico de trastornos inflamatorios
BRPI0920170A2 (pt) métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
Liu et al. PPM1F in hippocampal dentate gyrus regulates the depression-related behaviors by modulating neuronal excitability
Karelina et al. Social contact influences histological and behavioral outcomes following cerebral ischemia
CL2013000709A1 (es) Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10).
BR112017003552A2 (pt) ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total?
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
ES2671248T3 (es) Métodos para tratar el cáncer que comprenden un guiado por NQO1
AR086673A1 (es) RESPUESTAS MEJORADAS MEDIADAS POR LES-DC DE CELULAS B QUE SECRETAN IgG E IgA

Legal Events

Date Code Title Description
FB Suspension of granting procedure